Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials
- DOI
- 10.1016/j.critrevonc.2026.105677
- Published
- 2026-12
- Container
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105677,
title = {Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials},
author = {Fabrizio Citarella and Matteo Fiorenti and Cristina Fragale and Claudio Sini and Francesco Passiglia and Alessio Cortellini and Giuseppe Bronte},
year = {2026},
journal = {Critical Reviews in Oncology/Hematology},
doi = {10.1016/j.critrevonc.2026.105677},
url = {https://doi.org/10.1016/j.critrevonc.2026.105677}
}RIS
TY - JOUR TI - Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials AU - Fabrizio Citarella AU - Matteo Fiorenti AU - Cristina Fragale AU - Claudio Sini AU - Francesco Passiglia AU - Alessio Cortellini AU - Giuseppe Bronte PY - 2026 JO - Critical Reviews in Oncology/Hematology DO - 10.1016/j.critrevonc.2026.105677 UR - https://doi.org/10.1016/j.critrevonc.2026.105677 ER -
APA
Citarella, F., Fiorenti, M., Fragale, C., Sini, C., Passiglia, F., Cortellini, A., & Bronte, G. (2026). Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2026.105677
Source records
- crossref · retrieved 2026-11-09T22:10:31.712Z